• A Headlands Research Site   
    Headlands Research White Logo
    • About Headlands Research
    • Capabilities
    • Site Network
    • Team
Toronto Memory Program
  • Facebook
  • Twitter
  • LinkedIn
Donate Now
  • About Us
    • Medical Director
    • Our Team
    • Our Facility
    • Careers
  • Patients
    • Memory Clinic
    • Movement Disorders Clinic
    • Free Memory Assessment
    • Frequently Asked Questions
    • Clinical Trials
  • Physicians
  • Sponsors
  • Clinical Trials
    • Current Studies
    • Free Memory Assessment
    • Frequently Asked Questions
  • Media
  • Contact

Media

 

An experimental Alzheimer’s drug could be approved next year. But it comes with risks

An experimental Alzheimer's drug could be approved next year. But it comes with risks

Researchers say the experimental Alzheimer's drug Lecanemab represents an important advance and is likely to get FDA approval in 2023, despite some safety concerns.

To read more, click on the link below.

https://www.npr.org/2022/12/06/1140894394/an-experimental-alzheimers-drug-could-be-approved-next-year-but-it-comes-with-ri

Recent Posts

  • Hope and anxiety surround new Alzheimer’s drug lecanemab
  • Experimental drug appears to slow progression of Alzheimer’s disease in clinical trial but raises safety concerns
  • A New Drug Could Slow Alzheimer’s Disease, Data Show
  • A potential breakthrough in Alzheimer’s research needs Canadians’ help to move forward
  • An experimental Alzheimer’s drug could be approved next year. But it comes with risks
  • Ontario not ready for new Alzheimer’s treatment
  • Assessing Lecanemab’s Effect in Early Alzheimer Disease: Sharon Cohen, MD, FRCPC
  • Dr. Sharon Cohen on Medcan’s podcast series called Eat, Move, Think!
  • Dr. Sharon Cohen on CanadaTalks with Matt Gurney
  • CTV News Channel with Dr. Sharon Cohen on FDA approval of Aducanumab

Media Requests

If your organization would like to make a request, please use one of the following two options:

  • Call: (416) 386-9761 Ext. 364
  • Email: media@memorydisorders.ca
Latest Tweets

Toronto Memory Program is proud to have screened the first Canadian participant in Biogen's ENVISION study of #aducanumab today.

A HUGE ...thank you provided to our clinical trial participants and their contribution to research and to the generation of new knowledge.

Reply on Twitter 1616520995346456576 Retweet on Twitter 1616520995346456576 0 Like on Twitter 1616520995346456576 0 Twitter 1616520995346456576

Dr. Sharon Cohen of the Toronto Memory Program provided perspective on the steps the general public can take toward reducing the risk of ...Alzheimer disease and initiating treatment early when needed.

Improving Awareness of Cognitive Decline and Building on Lecanemab’s Success: Sharon Cohen, MD, FRCPC

The behavioral neurologist and medical director of the Toronto Memory Program provided perspective on the steps the ...

www.neurologylive.com

Reply on Twitter 1614280840690671616 Retweet on Twitter 1614280840690671616 2 Like on Twitter 1614280840690671616 3 Twitter 1614280840690671616
Load More...
Toronto Memory Program

A Headlands Research Company

  • Facebook
  • Twitter
  • LinkedIn
  • About Us
  • Patients
  • Physicians
  • Sponsors
  • Studies
  • In the Media
  • Contact Us


Monday - Friday: 8am - 4pm


Headlands Research Logo



© 2023 Toronto Memory Program. All rights reserved.